Cell-based assays can be precise and easy to perform. However, well characterized cells and cell culture methods are critical to assay success. Mr. Merges' presentation will describe the options and steps required for obtaining reproducible cell-based assay results. A case study will address documentation, training, equipment, supplies, and reagent issues.
The BEBPA bioassay conference is designed by practicing scientists to tackle topics to help develop, validate and maintain a bioassay. For more information on this event, please click here .
Currently, Michael Merges is Director of Catalent's Biopharmaceutical Support Services, focusing on the transfer, development, validation, and performance of bioassays, immunoassays, microbiological assays, and viral clearance assays. Mr. Merges has experience with many techniques, including cell-based (primary cells and cell lines) bioassays, immunological/neutralization assays, ELISA, and Flow Cytometry. He recently joined Catalent from Lonza where he was Associate Director of Lonza's Bioservices. Prior to that he was at the University of Maryland's Institute of Human Virology where he served as the Institute's Research Supervisor. He has also conducted viral immunology research at the National Cancer Institute and Johns Hopkins University. He obtained his Bachelors Degree in Microbiology from The Pennsylvania State University and his Masters Degree in Microbiology/Virology from Hood College.
Companies in this press-release
